IL-23
List of Advanced Rx Recommended For Moderate to Severe UC Expands
The AGA has released an updated guideline on pharmacologic management of adult outpatients with UC that, for the ...
FEBRUARY 4, 2025
New AGA Living Guideline Expands Recommended Drugs for Moderate to Severe UC
The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...
NOVEMBER 26, 2024
IBD Clinical Trials at a Crossroads
Inflammatory bowel disease clinical trials are facing headwinds, with challenges in recruitment and trial design.
OCTOBER 22, 2024
The ABCs of Optimizing Drug Sequencing for IBD
The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...
OCTOBER 13, 2024
FDA Approves Guselkumab for UC
The FDA has approved guselkumab (Tremfya, Janssen) for patients with moderately to severely active ulcerative ...
SEPTEMBER 12, 2024
Anti–IL-23 Agents Effective After Prior UC Treatment Failure
VANCOUVER, B.C.—Two different monoclonal antibodies targeting the interleukin-23 p19 subunit achieved all of ...
JANUARY 22, 2024
More Insight Into Anti-Interleukins
This month’s report focuses on the anti-interleukin treatments for inflammatory bowel disease, specifically ...
SEPTEMBER 11, 2023
